News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,903 Results
Type
Article (40014)
Company Profile (250)
Press Release (664638)
Multimedia
Podcasts (60)
Webinars (14)
Section
Business (204278)
Career Advice (2011)
Deals (35453)
Drug Delivery (95)
Drug Development (81140)
Employer Resources (172)
FDA (16249)
Job Trends (14887)
News (345503)
Policy (32606)
Tag
Academia (2556)
Accelerated approval (10)
Adcomms (22)
Allergies (95)
Alliances (49569)
ALS (108)
Alzheimer's disease (1444)
Antibody-drug conjugate (ADC) (151)
Approvals (16248)
Artificial intelligence (311)
Autoimmune disease (28)
Automation (19)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (122)
Biotechnology (175)
Bladder cancer (93)
Brain cancer (34)
Breast cancer (366)
Cancer (2868)
Cardiovascular disease (213)
Career advice (1682)
Career pathing (30)
CAR-T (185)
CDC (30)
Cell therapy (500)
Cervical cancer (22)
Clinical research (66858)
Collaboration (1014)
Company closure (3)
Compensation (686)
Complete response letters (23)
COVID-19 (2624)
CRISPR (56)
C-suite (328)
Cystic fibrosis (112)
Data (3002)
Decentralized trials (2)
Denatured (20)
Depression (61)
Diabetes (346)
Diagnostics (6424)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (138)
Drug pricing (121)
Drug shortages (28)
Duchenne muscular dystrophy (126)
Earnings (87453)
Editorial (40)
Employer branding (21)
Employer resources (148)
Events (113745)
Executive appointments (845)
FDA (17902)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (932)
Gene editing (129)
Generative AI (22)
Gene therapy (374)
GLP-1 (783)
Government (4502)
Grass and pollen (4)
Guidances (181)
Healthcare (18839)
HIV (40)
Huntington's disease (30)
IgA nephropathy (39)
Immunology and inflammation (147)
Immuno-oncology (8)
Indications (39)
Infectious disease (2796)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (120)
Interviews (312)
IPO (16591)
IRA (44)
Job creations (3637)
Job search strategy (1424)
Kidney cancer (13)
Labor market (52)
Layoffs (492)
Leadership (19)
Legal (7929)
Liver cancer (79)
Longevity (11)
Lung cancer (400)
Lymphoma (209)
Machine learning (11)
Management (58)
Manufacturing (387)
MASH (90)
Medical device (13462)
Medtech (13467)
Mergers & acquisitions (19582)
Metabolic disorders (849)
Multiple sclerosis (97)
NASH (16)
Neurodegenerative disease (113)
Neuropsychiatric disorders (32)
Neuroscience (2120)
NextGen: Class of 2025 (6517)
Non-profit (4488)
Now hiring (47)
Obesity (428)
Opinion (217)
Ovarian cancer (101)
Pain (106)
Pancreatic cancer (120)
Parkinson's disease (186)
Partnered (22)
Patents (299)
Patient recruitment (166)
Peanut (50)
People (57689)
Pharmaceutical (63)
Pharmacy benefit managers (21)
Phase I (20829)
Phase II (29449)
Phase III (21919)
Pipeline (1636)
Policy (200)
Postmarket research (2563)
Preclinical (8871)
Press Release (64)
Prostate cancer (140)
Psychedelics (37)
Radiopharmaceuticals (253)
Rare diseases (458)
Real estate (5917)
Recruiting (66)
Regulatory (22637)
Reports (50)
Research institute (2326)
Resumes & cover letters (350)
Rett syndrome (9)
RNA editing (8)
RSV (49)
Schizophrenia (86)
Series A (157)
Series B (108)
Service/supplier (11)
Sickle cell disease (60)
Special edition (18)
Spinal muscular atrophy (148)
Sponsored (32)
Startups (3588)
State (2)
Stomach cancer (14)
Supply chain (76)
Tariffs (57)
The Weekly (38)
Vaccines (779)
Venture capital (54)
Weight loss (257)
Women's health (47)
Worklife (16)
Date
Today (89)
Last 7 days (358)
Last 30 days (1883)
Last 365 days (31242)
2025 (16800)
2024 (35219)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (720)
Alabama (61)
Alaska (7)
Arizona (244)
Arkansas (13)
Asia (38212)
Australia (6232)
California (7441)
Canada (2360)
China (671)
Colorado (320)
Connecticut (318)
Delaware (192)
Europe (82109)
Florida (1118)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (637)
India (27)
Indiana (361)
Iowa (16)
Japan (229)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1023)
Massachusetts (5529)
Michigan (246)
Minnesota (450)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (81)
New Hampshire (66)
New Jersey (2079)
New Mexico (28)
New York (2085)
North Carolina (1080)
North Dakota (8)
Northern California (3277)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1612)
Puerto Rico (17)
Rhode Island (36)
South America (1098)
South Carolina (34)
South Dakota (1)
Southern California (2784)
Tennessee (126)
Texas (1126)
United States (27575)
Utah (220)
Virginia (185)
Washington D.C. (72)
Washington State (632)
West Virginia (4)
Wisconsin (66)
704,903 Results for "biosyent inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioSyent Declares Second Quarter 2025 Dividend
May 15, 2025
·
1 min read
Press Releases
BioSyent Releases Financial Results for First Quarter 2025
May 15, 2025
·
6 min read
Press Releases
BioSyent Schedules First Quarter Earnings Release for May 15, 2025
May 9, 2025
·
1 min read
BioSyent In-Licenses Endocrinology Product for Canada
BioSyent Inc. is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc., has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada.
June 12, 2024
·
2 min read
Business
BioSyent Announces Extension of RepaGyn® and Proktis-M® Agreement
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has extended its Exclusive License and Distribution Agreement with its European partner for the RepaGyn® and Proktis-M® products, extending BioSyent Pharma’s exclusive Canadian rights to these products until 2032.
April 15, 2024
·
2 min read
Press Releases
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2024
March 14, 2025
·
6 min read
BioSyent Releases Financial Results for Q1 2024
BioSyent Inc. released its financial results for the three months ended March 31, 2024.
May 16, 2024
·
4 min read
Press Releases
BioSyent Declares First Quarter 2025 Dividend
January 30, 2025
·
1 min read
BioSyent to Present at 2024 Bloom Burton & Co. Healthcare Investor Conference
BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co. Healthcare Investor Conference.
April 10, 2024
·
2 min read
Press Releases
BioSyent Schedules Fourth Quarter and Full Year 2024 Earnings Release for March 13, 2025
March 6, 2025
·
1 min read
1 of 70,491
Next
